CRP AND ADIPONECTIN AS MARKERS FOR INSULIN RESISTANCE

CRP 和脂联素作为胰岛素抵抗的标志物

• 批准号: 7381012
• 负责人: Yuan-Xiang Meng
• 金额: $ 3.91万
• 依托单位: MOREHOUSE SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-01 至 2007-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7381012
• 关键词: CRP; ADIPONECTIN; MARKERS; INSULIN; RESISTANCE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of the study is to determine whether biomarkers such as the high sensitivity C-reactive protein (Hs CRP) and adiponectin can be used as clinically useful assays for insulin resistance (IR) in non-diabetic, obese and non-obese African Americans (AA) and Caucasian Americans (CA). IR is a disorder in which the cells do not use insulin properly. Experimental and epidemiological studies have demonstrated the strong associations among IR and a variety of diseases, including vascular diseases (e.g., hypertension, CHD, and CVA), dys-lipidemia, diabetes (DM), systemic inflammation, and atherogenesis. Although IR can be measured by a variety of methods, there are no clear cut-offs for the diagnosis of IR and most of methods are difficult to apply in daily clinical practice, in particular, for outpatient care settings. In this project, we hypothesize that CRP is positively correlated to adiposity and IR (a ¿pro-inflammatory¿ state) whereas adiponectin is inversely correlated to adiposity and IR in non-diabetic AA and CA. The predictive value of clinically useful biomarker indices, such as CRP and adiponectin, is different in the two ethnic populations. The specific aims of the study are: 1) Establish the relationship between CRP and adiponectin plasma levels with simple assays of IR (eg HOMA) in a randomly ascertained, population-based sample of non-diabetic, obese and non-obese subjects composed of both AA and CA in the metro-Atlanta area. 2) Test the hypothesis that the relationship between CRP and adiponectin plasma levels with IR differs in AA versus CA. 3) Utilize a ROC analysis to determine cut-points for CRP or adiponectin levels that distinguish subjects with clinically significant and non-significant IR in each race/ethnic group. 4) Perform a pilot validation study to test the predictive value of CRP and adiponectin for IR by using the frequently-sampled intravenous glucose tolerance test (FSIGT)) in a subset of our population-based sample in the controlled setting of the Clinical Research Center. This study may lead to the early identification of individuals with IR using simplified practical approach. It will help us to develop new strategies for primary prevention of CHD, CVA, and DM. The interventions aimed at improving IR may provide additional therapeutic benefits to reduce the morbidity and mortality of CVA and DM.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。该研究的目的是确定生物标志物（例如高灵敏度C反应蛋白（HS CRP）和脂联素是否可以用作在非糖尿病，肥胖，肥胖和非肥胖的非洲裔美国人（AA）和毒素中的胰岛素抵抗（IR）临床上有用的组装（IR）。 IR是一种细胞无法正确使用胰岛素的疾病。 Experimental and epidemiological studies have demonstrated the strong associations among IR and a variety of diseases, including vascular diseases (e.g., hypertension, CHD, and Although IR can be measured by a variety of methods, there are no clear cut-offs for the diagnosis of IR and most of methods are difficult to apply in daily clinical practice, in particular, for outpatient care settings. In this project, we hypothesize that CRP is positively与肥胖和IR相关（促炎状态），而脂肪素与非糖尿病的AA和ca中的IR相关。在一个随机确定的，基于人群的非糖尿病，肥胖和非肥胖受试者的样本中，对IR（例如HOMA）的评估。 2）检验以下假设：CRP与脂联素血浆水平之间的关系与AA相比CA的IR差异。 3）利用ROC分析来确定CRP或脂联素水平的切点，这些降低是在每个种族/种族组中区分具有临床意义和不显着性IR的受试者。 4）执行一项试验验证研究，通过在临床研究中心的受控环境中，使用经常采样的静脉葡萄糖耐受性测试（FSIGT）来测试IR的CRP和脂联素对IR的预测价值。这项研究可能会导致使用简化的实际方法对患有IR的个体进行早期识别。它将帮助我们制定新的冠心病，CVA和DM的新策略。旨在改善IR的干预措施可能会提供额外的治疗益处，以降低CVA和DM的发病率和死亡率。